PTX-COVID19-B

PTX-COVID19-B
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number

PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco–based Eric Marcusson[1] in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B[2] in less than four weeks, according to the Calgary Herald.[3] Human trials with sixty volunteers began on January 26, 2021, in Toronto.[4][5][6]

Providence, which has no manufacturing facilities, partnered with Calgary-based Northern mRNA—the "anchor tenant" in their future manufacturing facilities pending financing.[2]

On April 30, 2021, Sorenson announced that Providence Therapeutics would be leaving Canada and any vaccine that it developed would not be manufactured in Canada.[2]

  1. ^ "Canadian company urges human trials after COVID-19 vaccine results in mice". Lethbridge News Now. 5 August 2020. Retrieved 19 March 2021.
  2. ^ a b c Tasker JP (30 April 2021). "COVID-19 vaccine maker Providence says it's leaving Canada after calls for more federal support go unanswered". CBC News. Retrieved 1 May 2021.
  3. ^ Cite error: The named reference calgaryherald_Stephenson_20210205 was invoked but never defined (see the help page).
  4. ^ Clinical trial number NCT04765436 for "PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64" at ClinicalTrials.gov
  5. ^ "Providence Therapeutics Holdings Inc: PTX-COVID19-B". Montreal: McGill University. Retrieved 19 March 2021.
  6. ^ "Made-in-Canada coronavirus vaccine starts human clinical trials". Canadian Broadcasting Corporation. 26 January 2021.